| Autor: |
GOMEZ, JUANA CARRETERO, ENA, JAVIER, SEGUI-RIPOLL, JOSE MIGUEL, CARRASCO-SÁNCHEZ, FRANCISCO JAVIER, AREVALO LORIDO, JOSE CARLOS, TEMBRA, MANUEL SUAREZ, VARELA, JOSE MANUEL, GOMEZ-HUELGAS, RICARDO |
| Zdroj: |
Diabetes; 2020 Supplement, Vol. 69, pN.PAG-N.PAG, 1p |
| Abstrakt: |
Aim: To analyze changes on UACR in T2DM patients according to treatment schedule groups (GLP-1RA or SGLT2i). Methods: Observational, prospective, multicenter study. Patients were stratified according to predetermined treatment schedule groups (successively vs.simultaneously). Results: 178 patients (58.6% males, age 61.9+/-10.0 years). Table 1 shows baseline findings by groups. Initial UACR was 19.6+/-52.5 mg/g and initial UACR >30 mg/g (n=68) was 95.1+/-222 mg/g. At 26 weeks significant % change in UACR and UACR>30mg/g was found (4.35+/-30** and 48.8+/105.5**), greater when SGLT2i is added (90.5+/-276.5 *) (Table 2). Discussion: Our results shows that the combination GLP-1ra-SGLT2i reduces UACR, especially if macroalbuminuria is present and is correlated to improvement in either HbA1c, weight and SBP. Disclosure: J. Carretero Gomez: None. J. Ena: None. J. Segui-Ripoll: None. F. Carrasco-Sánchez: None. J. Arevalo Lorido: None. M. Suarez Tembra: None. J. Varela: None. R. Gomez-Huelgas: None. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
